Definitive Healthcare Corp. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The company provides healthcare commercial intelligence through a subscription SaaS platform and reported approximately 3,000 customers. 2022 comparative financial results were restated, principally for previously unaccrued sales-tax obligations.
Financial performance and position
| Metric | Q2 2023 | Q2 2022, restated | Six months 2023 | Six months 2022, restated |
|---|---|---|---|---|
| Revenue | $61.0 million | $54.5 million | $120.2 million | $104.7 million |
| GAAP gross profit / margin | $49.8 million / 82% | $42.8 million / 78% | $97.1 million / 81% | $81.6 million / 78% |
| Operating loss | $(12.1) million | $(11.9) million | $(24.3) million | $(23.4) million |
| Net loss | $(11.6) million | $(10.1) million | $(27.6) million | $(23.2) million |
| Net loss attributable to Definitive Healthcare Corp. | $(8.6) million | $(5.5) million | $(20.6) million | $(14.1) million |
| Adjusted EBITDA / margin | $17.2 million / 28% | $16.3 million / 30% | $32.9 million / 27% | $30.3 million / 29% |
Q2 revenue grew 12%, led by subscription services; subscription revenue was $59.3 million. New-customer additions contributed $7.9 million, partly offset by a $1.4 million decline from customers carried over from the prior year. For the first half, revenue increased 15%; new customers and the Analytical Wizards acquisition more than offset a $1.8 million decline from existing customers. Despite higher gross profit, operating expenses rose 13% in Q2 and 16% for the first half. Increased stock-based compensation, personnel costs, data and hosting costs, sales taxes, and restructuring contributed to expense pressure.
Cash flow and liquidity: First-half operating cash flow was $27.0 million, compared with $29.1 million a year earlier. Investing activities used $32.1 million, including net purchases of short-term investments; financing activities used $9.2 million. Cash and cash equivalents were $132.4 million and short-term investments were $218.5 million at June 30, 2023. The $75 million revolving facility was undrawn. Current assets were $421.0 million versus current liabilities of $148.1 million.
Debt: The term loan had $263.0 million principal outstanding, with a 6.95% effective interest rate; $12.0 million was classified as current. The loan matures in September 2026, and approximately $220 million is due as a balloon payment at maturity. The company reported compliance with credit-facility covenants. Interest-rate swaps hedge part of the floating-rate exposure.
Other balance-sheet items: Total assets were $2.105 billion, including $1.325 billion of goodwill and $325.8 million of net intangible assets. The tax receivable agreement liability was $170.7 million. The company held 73.1% of Definitive OpCo; the remaining 26.9% was reported as noncontrolling interests.
Changes, outlook and notable matters
- Demand and outlook: Management reported longer sales cycles, deferred purchasing decisions, stricter customer approvals, and heightened churn, especially in life sciences and provider markets. It expects 2023 revenue growth to be lower than in 2022 and NDR to decline slightly relative to year-end 2022 unless macroeconomic conditions improve. No specific full-year revenue or earnings guidance is stated in the provided filing text.
- Margins and costs: Management expects gross profit to increase in 2023 with revenue growth, but gross margin to decrease modestly, partly due to expanded third-party data sources. Cost of revenue as a share of revenue may modestly increase. Rising interest rates are expected to increase interest expense on unhedged debt.
- Sales-tax issue and restatement: The company identified that it had not collected or accrued sales taxes on certain services in some states. The June 30 accrual was $8.8 million, including assumed maximum penalties and interest. The company restated prior-period statements, including 2022 comparisons, and said adjustments may follow as it obtains customer exemption documentation or tax-authority relief.
- Controls: A material weakness in controls over sales-tax identification, collection, remittance, and accounting remained unremediated at June 30, 2023. Management concluded disclosure controls and procedures were not effective. Remediation work was underway.
- Restructuring: The January 2023 plan generated $2.5 million of charges in the first half, with $0.2 million of additional expense expected through Q3. A subsequent plan announced July 27 was expected to incur $1.8–$2.0 million of pre-tax cash charges in Q3 and be substantially complete by quarter-end.
- Subsequent acquisition: The company completed its acquisition of Populi on July 21, 2023, for $52.0 million in cash, subject to working-capital adjustments, with possible additional milestone-based consideration. Purchase accounting was incomplete when the filing was prepared.
- Risks and contingencies: Management cited macroeconomic uncertainty, inflation, interest rates, customer spending and churn, financial-institution liquidity risks, and potential difficulty obtaining future financing. The company expects liquidity from operations, cash and investments, and its revolver to meet needs for at least 12 months. Ordinary-course legal matters were not expected by management to have a material adverse effect.
Most important facts for investors to verify
- Progress and effectiveness of remediation for the sales-tax material weakness, and whether further restatements or accrual changes are needed.
- Customer retention, churn, NDR, renewal trends, and the extent to which delayed buying decisions affect revenue growth.
- Whether higher operating costs and stock-based compensation continue to offset revenue growth and adjusted EBITDA gains.
- Cash generation and liquidity after the $52.0 million Populi acquisition, alongside debt service, interest costs, and the 2026 balloon payment.
- Final Populi purchase accounting and any contingent consideration, as well as the cost and expected savings from restructuring.
- Assumptions underlying the $8.8 million sales-tax accrual and the $170.7 million tax receivable agreement liability.